TWi Biotechnology sees hints of success in anti-inflammatory approach to type 2 diabetes
This article was originally published in Scrip
Executive Summary
The Taiwanese company TWi Biotechnology is having some success with an oral small-molecule IL-1beta inhibitor in the treatment of type 2 diabetes, Phase IIb data suggest.